BRPI0809971A2 - Derivados de piridina e pirimidina como antagosnistas de mglur2 - Google Patents
Derivados de piridina e pirimidina como antagosnistas de mglur2Info
- Publication number
- BRPI0809971A2 BRPI0809971A2 BRPI0809971-5A2A BRPI0809971A BRPI0809971A2 BR PI0809971 A2 BRPI0809971 A2 BR PI0809971A2 BR PI0809971 A BRPI0809971 A BR PI0809971A BR PI0809971 A2 BRPI0809971 A2 BR PI0809971A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagosnists
- mglur2
- pyridine
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105429 | 2007-04-02 | ||
| PCT/EP2008/053460 WO2008119689A1 (en) | 2007-04-02 | 2008-03-25 | Pyridine and pyrimidine derivatives as mglur2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0809971A2 true BRPI0809971A2 (pt) | 2014-10-07 |
Family
ID=39457413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809971-5A2A BRPI0809971A2 (pt) | 2007-04-02 | 2008-03-25 | Derivados de piridina e pirimidina como antagosnistas de mglur2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8012986B2 (pt) |
| EP (1) | EP2142527B1 (pt) |
| JP (1) | JP5303544B2 (pt) |
| KR (1) | KR101143152B1 (pt) |
| CN (1) | CN101641346B (pt) |
| AR (1) | AR065891A1 (pt) |
| AT (1) | ATE493400T1 (pt) |
| AU (1) | AU2008233956B2 (pt) |
| BR (1) | BRPI0809971A2 (pt) |
| CA (1) | CA2681733A1 (pt) |
| CL (1) | CL2008000936A1 (pt) |
| DE (1) | DE602008004236D1 (pt) |
| IL (1) | IL200780A (pt) |
| MX (1) | MX2009010505A (pt) |
| PE (1) | PE20090103A1 (pt) |
| TW (1) | TW200845999A (pt) |
| WO (1) | WO2008119689A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009203693B2 (en) * | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| US20130137865A1 (en) | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| JP2014062047A (ja) * | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
| WO2013041652A1 (en) * | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| WO2013119895A1 (en) | 2012-02-08 | 2013-08-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN104736140A (zh) | 2012-10-23 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 用于治疗自闭症的mGlu2/3拮抗剂 |
| JP2017513844A (ja) | 2014-04-23 | 2017-06-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト |
| WO2015191630A1 (en) * | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| PT3494119T (pt) | 2016-07-29 | 2024-12-10 | Pgi Drug Discovery Llc | Compostos e composições e seus usos |
| CA3070993C (en) | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc. | ISOCHROMANE COMPOUNDS AND THEIR USES |
| KR20210022681A (ko) * | 2018-06-22 | 2021-03-03 | 바이엘 악티엔게젤샤프트 | 트리시클릭 화합물의 제조 방법 |
| EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03007513A (es) * | 2001-02-21 | 2004-07-30 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. |
| CN100387594C (zh) * | 2003-04-03 | 2008-05-14 | 麦克公司 | 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂 |
| CA2521399A1 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| US7442797B2 (en) * | 2003-11-04 | 2008-10-28 | Takasago International Corporation | Platinum complex and light emitting device |
| US20060173048A1 (en) | 2005-02-03 | 2006-08-03 | Mcarthur Silvia G | Imidazole derivatives |
| WO2007110337A1 (en) | 2006-03-29 | 2007-10-04 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
| US20070236568A1 (en) | 2006-04-11 | 2007-10-11 | Metke Anthony R | Method and system for communicating incident scene information |
-
2008
- 2008-03-24 US US12/053,648 patent/US8012986B2/en not_active Expired - Fee Related
- 2008-03-25 AT AT08718155T patent/ATE493400T1/de active
- 2008-03-25 MX MX2009010505A patent/MX2009010505A/es active IP Right Grant
- 2008-03-25 AU AU2008233956A patent/AU2008233956B2/en not_active Ceased
- 2008-03-25 CN CN2008800096420A patent/CN101641346B/zh not_active Expired - Fee Related
- 2008-03-25 EP EP08718155A patent/EP2142527B1/en not_active Not-in-force
- 2008-03-25 JP JP2010501476A patent/JP5303544B2/ja not_active Expired - Fee Related
- 2008-03-25 BR BRPI0809971-5A2A patent/BRPI0809971A2/pt not_active IP Right Cessation
- 2008-03-25 CA CA002681733A patent/CA2681733A1/en not_active Abandoned
- 2008-03-25 KR KR1020097020481A patent/KR101143152B1/ko not_active Expired - Fee Related
- 2008-03-25 WO PCT/EP2008/053460 patent/WO2008119689A1/en not_active Ceased
- 2008-03-25 DE DE602008004236T patent/DE602008004236D1/de active Active
- 2008-03-31 AR ARP080101333A patent/AR065891A1/es unknown
- 2008-03-31 TW TW097111725A patent/TW200845999A/zh unknown
- 2008-04-01 PE PE2008000591A patent/PE20090103A1/es not_active Application Discontinuation
- 2008-04-01 CL CL200800936A patent/CL2008000936A1/es unknown
-
2009
- 2009-09-07 IL IL200780A patent/IL200780A/en not_active IP Right Cessation
-
2011
- 2011-07-08 US US13/178,531 patent/US8415380B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200845999A (en) | 2008-12-01 |
| ATE493400T1 (de) | 2011-01-15 |
| CL2008000936A1 (es) | 2008-10-03 |
| KR20090117902A (ko) | 2009-11-13 |
| AU2008233956B2 (en) | 2013-05-02 |
| JP5303544B2 (ja) | 2013-10-02 |
| US20110263615A1 (en) | 2011-10-27 |
| MX2009010505A (es) | 2009-10-19 |
| DE602008004236D1 (de) | 2011-02-10 |
| CN101641346B (zh) | 2013-11-06 |
| JP2010524852A (ja) | 2010-07-22 |
| EP2142527A1 (en) | 2010-01-13 |
| US8415380B2 (en) | 2013-04-09 |
| WO2008119689A1 (en) | 2008-10-09 |
| CA2681733A1 (en) | 2008-10-09 |
| US8012986B2 (en) | 2011-09-06 |
| IL200780A (en) | 2013-01-31 |
| KR101143152B1 (ko) | 2012-05-08 |
| EP2142527B1 (en) | 2010-12-29 |
| PE20090103A1 (es) | 2009-02-13 |
| CN101641346A (zh) | 2010-02-03 |
| AU2008233956A1 (en) | 2008-10-09 |
| AR065891A1 (es) | 2009-07-08 |
| IL200780A0 (en) | 2010-05-17 |
| US20080280924A1 (en) | 2008-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809971A2 (pt) | Derivados de piridina e pirimidina como antagosnistas de mglur2 | |
| BRPI0810202A2 (pt) | Derivados de piridina | |
| BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
| BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| ES2465673T9 (es) | Derivados de pirimidina | |
| BRPI0818658A2 (pt) | Derivados de piridina úteis como ativadores de glicoquinase | |
| BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
| EP2404918A4 (en) | pyridine | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| ZA200808191B (en) | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | |
| BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
| BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| BRPI0817935A2 (pt) | Derivados de biarila | |
| BR112012000763A2 (pt) | derivados de piridin-4-ila | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
| BRPI1016117A8 (pt) | derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| BRPI0822058A2 (pt) | Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7 | |
| BRPI0811115A2 (pt) | Compostos de heteroarilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |